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Abstract: The role of surgical resection in patients with meta-
static thyroid cancer is not clearly defined. Reported is a case of
concurrent thyroid metastases to the lungs and sternum treated
with total sternectomy followed by radioiodine therapy. A com-
prehensive review of the literature was also performed to evalu-
ate the characteristics of reported cases of sternal thyroid cancer
metastases treated with surgical resection. Overall, we demon-
strate that radical resection of sternal metastases can be per-
formed safely even in patients with poor prognosis to achieve
palliation and potentiation of radioiodine therapy for concurrent
metastases.
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Studies have shown that the prognosis of patients withthyroid cancer metastases to both bone and lung is
worse than for patients with either pulmonary or bony
metastases alone.1 However, these studies did not discern
whether the subset of patients with both types of lesions
who have resectable bony metastases have different out-
comes, by virtue of their postoperative potential to be
considered patients with lung metastases alone. By removing
two factors—large tumor burden and bony metastases—
that predict poor response to radioiodine (RAI), these
patients may be more likely to receive appropriate treat-
ment and achieve prolonged survival and/or quality of life.
Consequently, surgery has the potential to play a signifi-
cant role in providing not only palliation but also optimal
RAI therapy in a group of patients who may not otherwise
be considered candidates for such treatment. Here, we
present a case that illustrates how complete resection of a
large sternal thyroid cancer metastasis provided palliation
and the opportunity to treat concurrent pulmonary metas-
tases with RAI.
CASE REPORT AND METHODS
A 75-year-old woman presented to an outside hospi-
tal with left neck swelling and sternal pain. Chest com-
puted tomography (CT) performed on January 22, 2007,
revealed a thyroid mass extending into the superior medi-
astinum causing tracheal deviation. Also noted was a lytic
lesion involving the majority of the sternum (Figure 1A).
In addition, numerous pulmonary lesions were seen in
bilateral lung fields (Figure 1B). The patient had a normal
T4 level, with a slightly low thyroid-stimulating hormone
(0.11 mc IU/ml), and thyroglobulin (TG) levels exceeding
500 ng/ml. An open sternal biopsy revealed follicular
thyroid carcinoma. Because of the great tumor burden,
RAI was assumed to be ineffective. She was referred to our
institution for inclusion in an investigational trial. How-
ever, on consultation with thoracic surgery, her sternal
metastasis was deemed resectable. Intraoperatively, the
mass was found to extend from the sternomanubrial junc-
tion to the xiphoid (Figure 2A). Total sternectomy with 4
cm margins including costochondral joints and partial
resection of the manubrium was performed. Negative mar-
gins were achieved by frozen section analysis. Complex
sternal reconstruction was performed with methyl methac-
rylate sandwiched between two layers of polypropylene
mesh, which had been sutured with 0 Prolene to the edges
of the resected chest wall. Pectoralis major muscle flap
reconstruction was performed to cover the mesh and rein-
force the anterior chest. Completion thyroidectomy and
parathyroid autotransplant were performed before sternal
reconstruction.
The patient was discharged on postoperative day 11
after an uneventful postoperative course. Although her initial
biopsy had diagnosed follicular carcinoma (likely reflective
of sampling error), final pathology revealed the sternal mass
to be a poorly differentiated (insular) thyroid carcinoma,
14  8  7 cm, with a 5% component of follicular
carcinoma, involving soft tissues, bone, cartilage, and vessels
(Figure 2B).
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Twelve weeks later, the patient was treated with abla-
tive RAI, administered at a dose of 246 mc. Chest CT (Figure
1D) performed on July 16, 2007, revealed interval decrease of
the lung nodules seen on preoperative imaging. Her TG levels
had dropped to 96.6 ng/ml (from 500 ng/ml preopera-
tively). More than 1 year, the patient was still completely
asymptomatic but had developed rising TG levels. A repeat
positron emission tomography (PET)/CT scan revealed a lung
nodule that was ametabolic and unchanged in size from
previous scans and no new sternal or neck masses. Fine
needle aspiration of the thyroid bed was negative. The patient
underwent a second cycle of RAI for presumed recurrence,
and her TG level dropped again to 90 ng/ml. At her last
follow-up on March 20, 2009, more than 2 years after her
sternal resection, she was asymptomatic and doing well with
her daily activities.
A comprehensive PubMed search was performed to
identify all reported cases of sternectomy for thyroid cancer
metastases. Key words used included thyroid cancer, ster-
num, sternectomy, and metastasis. Limits were set for En-
glish language only.
RESULTS
Of the 10 cases reported (including this one), patient
ages ranged from 35 to 75 years (with an average of 58
years) and 90% of the patients were female. Sternal me-
tastases ranged in size from 4 to 14 cm, with an average
greatest dimension of 8.6 cm. The majority (80%) of
metastases originated from follicular carcinomas or poorly
differentiated thyroid cancers with follicular components.
Of the eight cases where symptoms were reported, six
patients (75%) presented with pain. Of the nine reports that
described the surgical resection, the majority (56%) had
partial sternectomies. Methods of reconstruction were var-
ied, although most involved use of a synthetic mesh. Only
one report described a postoperative complication. Fifty
percent of all patients had concurrent metastases, most
frequently to the lungs. Of the nine reports that addressed
the subject, eventual nonsternal recurrence was docu-
mented in 30% of cases. Each of these patients had
FIGURE 1. Computed tomogra-
phy (CT) imaging after surgery and
radioiodine (RAI) demonstrates sig-
nificant decrease in lung metasta-
ses and resolution of sternal mass.
A, Sternal mass before surgery. B,
Arrow localizes largest lung nodule
before therapy. C, Sternal recon-
struction after resection. D, Arrow
localizes same lung nodule after
therapy.
FIGURE 2. A, Resected sternal mass. B, Poorly differentiated
thyroid carcinoma exhibiting insular growth pattern. Rare
abortive follicles (block arrows) and scattered mitotic figures
(short arrow) can be identified (hematoxylin and eosin; origi-
nal magnification, 400).
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TABLE 1. Patient Information for Reported Cases of Sternal Thyroid Cancer Metastases
Case
No.
Age
(yr) Sex Size (cm) Diagnosis Symptoms
Other
Metastases Year Reported References
1 61 F 6  5  4.5 Follicular Pain None 2006 Eroglu et al.2
2 35 F 7  7 Poorly differentiated with
follicular component
Pain None 2000 Mishra et al.3
3 43 M 7  10 Follicular None Pulmonary, vertebral 2000 Mishra et al.3
4 69 F 8  4.5 Papillary Pain None 2004 Haraguchi et al.4
5 54 F 4  4 Follicular Pain Pulmonary 1995 Ozaki et al.5
6 48 F 8  6 Papillary Pain None 1995 Ozaki et al.5
7 59 F NR Follicular NR Left neck 2005 Meyer et al.6
8 62 F NR Poorly differentiated with
follicular component
NR Three lymph nodes 2001 Kinoglou et al.7
9 75 F 12  9 Follicular None None 1998 Muthuphei et al.8
10 75 F 14  8  7 Poorly differentiated with
follicular component
Pain Pulmonary 2008 Yanagawa et al.
NR  not reported.
TABLE 2. Treatment Information for Reported Cases of Sternal Thyroid Cancer Metastases
Case
No. Resection Reconstruction Margins Complications Follow-Up Recurrence
Additional
Treatment
1 Partial sternectomy, including
manubrium and attached
portions of bilateral clavicles
and costal cartilage
Gore-Tex soft-tissue patch,
bipedicled pectoralis
major flaps
NR None 1 yr No RAI
2 Partial sternectomy, medial 2
cm of clavicles, first and
second ribs
Marlex mesh NR None None Unknown None
3 Partial sternectomy, anterior
first 3 ribs, medial clavicles,
manubrium
Marlex mesh NR None NR No RAI, resection
of vertebral
metastasis
4 Subtotal sternectomy Marlex mesh sandwiched
between stainless steel
mesh
NR None 3 mo No None
5 Total sternectomy Artificial sternum made of
methyl methacrylate
secured with metallic
wires
NR None 2.5 yr (death) Yes (pulmonary
and bony
metastases)
RAI
6 Subtotal sternectomy Methyl methacrylate
sandwiched between
Marlex mesh
NR None 5 mo No None
7 Partial sternectomy Polypropylene mesh NR None 4.5 yr Yes (pulmonary
metastases,
local
recurrence in
the neck)
RAI 4
8 Partial sternectomy Marlex mesh, left pedicled
pectoralis major muscle
flap
Negative None 1 yr No External
radiation
9 NR Prolene mesh NR Bleeding, sepsis 1 mo (death) No None
10 Total sternectomy Methyl methacrylate
sandwiched between
layers of polypropylene
mesh, bipedicled
pectoralis major muscle
flaps
Negative None 2 yr Yes (unknown
location)
RAI 2
Partial sternectomy, 50% resection; subtotal sternectomy, 50% resection; total sternectomy, 100% resection.
NR, not reported; RAI, radioiodine.
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concurrent distant metastases at the time of resection and
postoperative RAI therapy. Follow-up and survival in this
group ranged from 1 to 4.5 years. Follow-up and survival
for all reports ranged from 1 month to 4.5 years2–8 (Tables
1 and 2). The patient highlighted in this report had 11
pulmonary nodules in the right lung field and 12 in the left
lung field before RAI, which were hypermetabolic on PET
scan. After therapy, she had four remaining on each side
that were PET negative. Preoperatively, she had two mea-
surable (10 mm) lesions, a right nodule measuring
11.7  11.7 mm and a left nodule measuring 10.6  8.3
mm. After RAI, these nodules decreased to 3.8 and 5.1mm
(in greatest dimensions), respectively.
DISCUSSION
Sternal resection is an important palliative option for
patients with thyroid cancer metastases to the sternum.
Consequences of large sternal metastases include pain,
ulceration, and dyspnea. These symptoms affect quality of
life and are not uncommon, as evidenced by the fact that
more than half of the patients in this review presented with
pain associated with their sternal metastases. In addition to
these morbidities, large sternal metastases can be directly
linked to mortality. Thyroid metastases to the sternum
have been specifically documented as a cause of immediate
death because of compression of the superior vena cava
and circulatory arrest.9
RAI is another potentially significant option for pa-
tients with thyroid cancer metastases to the sternum, es-
pecially those with concurrent metastases. The decision to
administer RAI depends on factors that are known to be
associated with response to therapy. Characteristics of a
good candidate for RAI therapy include younger age,
well-differentiated tumor, high-RAI uptake, small metas-
tases, pulmonary metastases, and stable or slow disease.
Characteristics of a patient unlikely to benefit from RAI
include older age, poorly differentiated tumor, no or low
radioiodine uptake, large metastases, bony metastases, and
rapidly progressive disease. Although the absolute benefit of
resecting solitary thyroid cancer bony metastases is contro-
versial, this form of cytoreduction is believed to be generally
important for both local palliation and the achievement of
tumoricidal doses of RAI to unresectable lesions. Smaller
retrospective studies also suggest that metastastectomy
plays an important role in thyroid cancer metastases when
used in conjunction with nonsurgical therapies such as
RAI.10 This combination of therapy is unlikely to provide
a cure, as suggested by the fact that the reviewed cases
with concurrent metastases treated with RAI after sternal
resection developed eventual recurrence of disease; how-
ever, it may still provide improved quality of life and
prolonged survival.
The patient highlighted in this report presented with
numerous qualifications for extremely poor prognosis:
large tumor burden, a bony lesion in addition to multiple
pulmonary metastases, advanced age, and a poorly differ-
entiated insular thyroid carcinoma. Overall, this represents
a difficult case where therapeutic guidelines are limited.
We contend that despite poor prognosis in metastatic
thyroid cancer, the treatment of sternal metastases with
sternectomy and reconstruction can safely provide such
patients with significant palliation and confer the addi-
tional benefit of potentiating RAI therapy for concurrent
metastases.
REFERENCES
1. Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic
modalities in patients with bone metastases of differentiated thyroid
carcinomas. J Clin Endocrinol Metab 2001;86:1568–1573.
2. Eroglu A, Karaoglanoglu N, Bilen H, Gursan N. Follicular thyroid
carcinoma: metastasis to the sternum, 13 years after total thyroidectomy.
Int J Clin Pract 2006;60:1506–1508.
3. Mishra A, Mishra SK, Agarwal A, Agarwal G, Agarwal SK. Surgical
treatment of sternal metastases from thyroid carcinoma: report of two
cases. Surg Today 2001;31:799–802.
4. Haraguchi S, Yamashita Y, Yamashita K, Hioki M, Matsumoto K,
Shimizu K. Sternal resection for metastasis from thyroid carcinoma and
reconstruction with the sandwiched Marlex and stainless steel mesh. Jpn
J Thorac Cardiovasc Surg 2004;52:209–212.
5. Ozaki O, Kitagawa W, Koshiishi H, Sugino K, Mimura T, Ito K.
Thyroid carcinoma metastasized to the sternum: resection of the sternum
and reconstruction with acrylic resin. J Surg Oncol 1995;60:282–285.
6. Meyer A, Behrend M. Partial resection of the sternum for osseous
metastasis of differentiated thyroid cancer: case report. Anticancer Res
2005;25:4389–4392.
7. Kinoglou G, Vandeweyer E, Lothaire P, Gebhart M, Andry G. Thyroid
carcinoma metastasis to the sternum: resection and reconstruction. Acta
Chir Belg 2001;101:253–255.
8. Muthuphei MN, Mabua MP. Retrosternal thyroid carcinoma metastatic
to the sternum: a case report. Cent Afr J Med 1998;44:292–293.
9. Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death
in thyroid carcinoma: clinicopathological analysis of 161 fatal cases.
J Clin Endocrinol Metab 1999;84:4043–4049.
10. Pak H, Gourgiotis L, Chang WI, et al. Role of metastasectomy in the
management of thyroid carcinoma: the NIH experience. J Surg Oncol
2003;82:10–18.
Journal of Thoracic Oncology • Volume 4, Number 8, August 2009 Resection of Thyroid Cancer Metastases
Copyright © 2009 by the International Association for the Study of Lung Cancer 1025
